Drug Treatments for Core Symptoms of Autism Spectrum Disorder: Unmet Needs and Future Directions
| Autor: | Paolo Curatolo, Valentina Postorino, Giulia Giovagnoli, Luigi Mazzone, Martina Siracusano |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
genetic pathways
0301 basic medicine Drug medicine.medical_specialty folinic acid media_common.quotation_subject Population Psychological intervention autism spectrum disorder pharmacological treatments mTOR bumetanide memantine arbaclofen oxytocin 03 medical and health sciences 0302 clinical medicine mental disorders Medicine Cognitive skill education Psychiatry media_common education.field_of_study business.industry medicine.disease Settore MED/39 - Neuropsichiatria Infantile Review article 030104 developmental biology Autism spectrum disorder Pediatrics Perinatology and Child Health Autism Neurology (clinical) Core symptoms business 030217 neurology & neurosurgery Clinical psychology |
| Zdroj: | Journal of Pediatric Neurology. 15:134-142 |
| ISSN: | 1875-9041 1304-2580 |
| DOI: | 10.1055/s-0037-1602823 |
| Popis: | Pharmacological treatments for core symptoms of Autism Spectrum Disorder (ASD) are still lacking. The clinical heterogeneity observed in this population (e.g., differences in cognitive functioning or in autism symptom severity) should be taken into account when a new drug is tested. Stratifying this population according to its neurobiological substrate could significantly improve our knowledge regarding the most appropriate pharmacological treatment for individual needs. In this review, we discuss the possible genetic and biological pathways, including the Glutamatergic, GABAergic, and mTOR systems, involved in the pathophysiology of autism, as well as the mechanisms that may be targeted by new drug interventions. Finally, we describe the current progress from the preclinical and clinical studies on some potential therapeutic options for ASD core symptoms. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|